Article
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
Melanoma research - 1 Jun 2014
Ng Yuen-Keng, Lee Jia-Ying, Supko Kathryn M, Khan Ayesha, Torres Salina M, Berwick Marianne, Ho Jonhan, Kirkwood John M, Siegfried Jill M, Stabile Laura P
Abstract excerpt
The BRAF inhibitor vemurafenib is currently used for treating patients with BRAF V600E mutant melanoma. However, the responses to vemurafenib are generally partial and of relatively short duration. Recent evidence suggests that activation of the epidermal growth factor receptor (EGFR)/erbB signaling pathway may be responsible for the development of BRAF inhibitor resistance in melanoma patients. In this study, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.